Medicine Monitoring To Improve

BMI's April 2009 prediction that pharmaceutical regulations in Hong Kong would be tightened has proved correct.[1] The Review Committee on Regulation of Pharmaceutical Products has recommended that the medicine supply chain be better protected, pharmacovigilance enhanced and risk communication increased. After the Review Committee's release of a final report later this year, we will upgrade Hong Kong's Pharmaceutical Business Environment Rating score for 'policy', which is currently six out of 10.

To read the full article, please choose one of the following options: